the global Viral Vector Development Market, which was forecast to be worth US$ 534 million in 2021, is expected to increase to US$3.2 billion by 2032, at a CAGR of 18.2% through 2032. The increased prevalence of target diseases and disorders, the accessibility of funding for therapeutic gene strategies, the efficacy of viral vectors in gene …